W146
目录号 : GC16621
W146是鞘氨醇-1-磷酸受体1（S1PR1）的选择性拮抗剂，EC50值为398nM。
Cas No.:909725-61-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
W146 is a selective antagonist of Sphingosine 1-phosphate receptors 1 (S1PR1) with an EC50 value of 398nM[1].W146 is widely used to investigate S1P/S1PR1-mediated biological processes.
In vitro, W146 (10μM) was employed for 30min in HEK293 and CHO-K1 cells stably expressing S1P receptor. W146 completely abolished a water-soluble highly-selective S1PR1 agonist CYM-5442- or S1P-induced S1PR1 internalization, phosphorylation and ubiquitination, and p42/p44 MAPK activation[2]. W146 (1µM) pretreated microglia for 30min before siponimod treatment and then the cells were stimulated with 1µg/mL LPS alone (for 24h) or 1µg/mL LPS (for 3.5h) plus 10µM inflammasome activator nigericin (for the final 30min). Pretreatment with W146 and siponimod significantly suppressed the production of interleukin-1β in activated microglia stimulated with lipopolysaccharide plus nigericin[3].W146 (10μM) was applied to cultured rat fat-pad endothelial cells (RFPECs) and human coronary artery endothelial cells for 10min and then the cells were exposed to S1P or plasma protein-containing media for 2 hours. W146 abolished the protective role of S1P and plasma proteins on the glycocalyx[4].
In vivo, W146 (10mg/kg) was administered intraperitoneally into non fasted Swiss mice and induced a significant but transient blood lymphopenia in mice and a parallel increase in CD4+ and CD8+ lymphocytes in lymph nodes[5].W146 (0.1mg/kg) was administrated into C57BL/6 mice via intraperitoneal injection daily for 3 days before animals subjected to 20 minutes of renal ischemia followed by 24 hours of reperfusion. W146-treated mice exhibited significantly exacerbated renal and hepatic injury[6]. W146 (5mg/kg) injected intraperitoneally 1h before AMD3100 administration significantly enhanced the mobilization of Kit+/Sca-1+/Lin− (KSL) hematopoietic stem and progenitor cells in C57BL/6 mice by approximately 8-fold[7].
References:
[1] M Germana Sanna, et al. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol. 2006 Aug;2(8):434-41. Epub 2006 Jul 9.
[2] Gonzalez-Cabrera P J, Jo E J, Sanna M G, et al. Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions. Mol Pharmacol. 2008 Nov;74(5):1308-18.
[3] Tarrasón G, Aulí M, Mustafa S, et al.The sphingosine-1-phosphate receptor-1 antagonist, W146, causes early and short-lasting peripheral blood lymphopenia in mice. Int Immunopharmacol. 2011 Nov;11(11):1773-9.
[4] Zeng Y, Adamson R H, Curry F R E, Tarbell J M.Sphingosine-1-phosphate protects endothelial glycocalyx by inhibiting syndecan-1 shedding. Am J Physiol Heart Circ Physiol. 2014 Feb;306(3):H363-72.
[5] Tarrasón G, Aulí M, Mustafa S,et al. The sphingosine-1-phosphate receptor-1 antagonist, W146, causes early and short-lasting peripheral blood lymphopenia in mice. Int Immunopharmacol. 2011 Nov;11(11):1773-9.
[6] Ham A, Kim M, Kim J Y, et al. Selective deletion of the endothelial sphingosine-1-phosphate 1 receptor exacerbates kidney ischemia-reperfusion injury. Kidney Int. 2014 Apr;85(4):807-23.
[7] Liu J J, Zhao J W, Lee J F, et al. 3-amino-4-(3-hexylphenylamino)-4-oxobutyl phosphonic acid (W146), a Selective Antagonist of Sphingosine-1-phospahte Receptor Subtype 1, Enhances AMD3100-stimulated Mobilization of Hematopoietic Stem Progenitor Cells in Animals. J Biochem Pharmacol Res. 2013 Dec;1(4):197-203.
W146是鞘氨醇-1-磷酸受体1（S1PR1）的选择性拮抗剂，EC50值为398nM[1]。W146广泛用于研究S1P/S1PR1介导的生物学过程。
体外实验中，W146（10μM）处理稳定表达S1P受体的HEK293和CHO-K1细胞30分钟，W146完全阻断了水溶性、高选择性S1PR1激动剂CYM-5442或S1P诱导的S1PR1内化、磷酸化、泛素化以及p42/p44 MAPK的激活[2]。在siponimod处理前，W146（1μM）预处理小胶质细胞30分钟，随后细胞单独用1μg/mL LPS刺激24小时，或1μg/mL LPS刺激3.5小时并在最后30分钟加入10μM炎症小体激活剂nigericin。W146和siponimod的预处理显著抑制了经LPS加nigericin激活的小胶质细胞中白细胞介素-1β的产生[3]。W146（10μM）处理培养的大鼠脂肪垫内皮细胞（RFPECs）和人冠状动脉内皮细胞10分钟，随后细胞暴露于S1P或含血浆蛋白的培养基中2小时，W146消除了S1P和血浆蛋白对糖萼的保护作用[4]。
在体内实验中，W146（10mg/kg）经腹腔注射给予非禁食的Swiss小鼠，诱导了显著但短暂的血液淋巴细胞减少，并伴随淋巴结中CD4+和CD8+淋巴细胞的平行增加[5]。W146（0.1mg/kg）经腹腔注射给予C57BL/6小鼠，每日一次，连续3天，随后进行20分钟肾脏缺血及24小时再灌注处理。W146处理的小鼠表现出明显加重的肾和肝损伤[6]。W146（5mg/kg）在AMD3100给药前1小时经腹腔注射，显著增强了C57BL/6小鼠中Kit+/Sca-1+/Lin−（KSL）造血干细胞和祖细胞的动员，增幅约达8倍[7]。
| Cell experiment [1]: | |
Cell lines | HEK293 and CHO-K1 cells stably expressing human S1P receptor 1 |
Preparation Method | The cells were incubated for 4h in serum-free DMEM. In the antagonist experiments, W146 were incubated with W146 for 30min at 10μM prior to agonist treatment. |
Reaction Conditions | 10μM; 30min |
Applications | W146 completely abolished a water-soluble highly-selective S1PR1 agonist CYM-5442- or S1P-induced S1PR1 internalization, phosphorylation and ubiquitination, and p42/p44 MAPK activation. |
| Animal experiment [2]: | |
Animal models | C57BL/6 mice |
Preparation Method | C57BL/6 mice (6–8 weeks old, 5 mice per group) were subcutaneously (s.c.) injected with AMD3100. To induce mobilization of hematopoietic stem progenitor cells, animals received AMD3100 at a dose of 5mg/kg of body weight. For combined treatments, W146 were injected intraperitoneally (i.p.; 5mg/kg) 1 hour prior to AMD3100 administration. |
Dosage form | 5mg/kg; i.p.; 1 hour prior to AMD3100 administration |
Applications | W146 significantly augmented AMD3100-induced KSL-HSPC mobilization into peripheral blood. |
References: | |
| Cas No. | 909725-61-7 | SDF | |
| 化学名 | (R)-(3-amino-4-((3-hexylphenyl)amino)-4-oxobutyl)phosphonic acid | ||
| Canonical SMILES | OP(O)(CC[C@H](C(NC1=CC(CCCCCC)=CC=C1)=O)N)=O | ||
| 分子式 | C16H27N2O4P | 分子量 | 342.37 |
| 溶解度 | 3eq. NaOH: 6.85mg/mL (20mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9208 mL | 14.6041 mL | 29.2082 mL |
| 5 mM | 584.2 μL | 2.9208 mL | 5.8416 mL |
| 10 mM | 292.1 μL | 1.4604 mL | 2.9208 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet